Antibodies against non-HLA targets are increasingly recognized in the context of transplant rejection. However, their specific role remains largely elusive, as evidence exists supporting both their occurrence as an epiphenomenon and their actual pathogenicity in the rejection process. Sutherland et al.
View Article and Find Full Text PDF